Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 351

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison

Open access
Ainsworth, Mark, Andersson, Monique, Auckland, Kathryn, Baillie, J Kenneth, Barnes, Eleanor, Beer, Sally, Beveridge, Amy, Bibi, Sagida, Blackwell, Luke, Borak, Martyna, Bown, Abbie, Brooks, Tim, Burgess-Brown, Nicola A, Camara, Susana, Catton, Matthew, Chau, Kevin K., Christott, Thomas, Clutterbuck, Elizabeth, Coker, Jesse, Cornall, Richard J, Cox, Stuart, Crawford-Jones, David, Crook, Derrick W, D'Arcangelo, Silvia, Dejnirattsai, Wanwisa, Dequaire, Julie M M, Dimitriadis, Stavros, Dingle, Kate E, Doherty, George, Dold, Christina, Dong, Tao, Dunachie, Susanna J, Ebner, Daniel, Emmenegger, Marc, Espinosa, Alexis, Eyre, David W, Fairhead, Rory, Fassih, Shayan, Feehily, Conor, Felle, Sally, Fernandez-Cid, Alejandra, Fernandez Mendoza, Maria, Foord, Thomas H, Fordwoh, Thomas, Fox McKee, Deborah, Frater, John, Gallardo Sanchez, Veronica, Gent, Nick, Georgiou, Dominique, Groves, Christopher J, Hallis, Bassam, Hammond, Peter M, Hatch, Stephanie B., Harvala, Heli J, Hill, Jennifer, Hoosdally, Sarah J, Horsington, Bryn, Howarth, Alison, James, Tim, Jeffery, Katie, Jones, Elizabeth, Justice, Anita, Karpe, Fredrik, Kavanagh, James, Kim, David S, Kirton, Richard, Klenerman, Paul, Knight, Julian C, Koukouflis, Leonidas, Kwok, Andrew, Leuschner, Ullrich, Levin, Robert, Linder, Aline, Lockett, Teresa, Lumley, Sheila F, Marinou, Spyridoula, Marsden, Brian D, Martinez, Jose, Martins Ferreira, Lucas, Mason, Lara, Matthews, Philippa C, Mentzer, Alexander J, Mobbs, Alexander, Mongkolsapaya, Juthathip, Morrow, Jordan, Mukhopadhyay, Shubhashish M M, Neville, Matthew J, Oakley, Sarah, Oliveira, Marta, Otter, Ashley, Paddon, Kevin, Pascoe, Jordan, Peng, Yanchun, Perez, Elena, Perumal, Prem K, Peto, Timothy E A, Pickford, Hayleah, Ploeg, Rutger J, Pollard, Andrew J, Richardson, Anastasia, Ritter, Thomas G, Roberts, David J, Rodger, Gillian, Rollier, Christine S, Rowe, Cathy, Rudkin, Justine K, Screaton, Gavin, Semple, Malcolm G, Sienkiewicz, Alex, Silva-Reyes, Laura, Skelly, Donal T, Sobrino Diaz, Alberto, Stafford, Lizzie, Stockdale, Lisa, Stoesser, Nicole, Street, Teresa, Stuart, David I, Sweed, Angela, Taylor, Adan, Thraves, Hannah, Tsang, Hoi P, Verheul, Marije K, Vipond, Richard, Walker, Timothy M, Wareing, Susan, Warren, Yolanda, Wells, Charlie, Wilson, Clare, Withycombe, Kate, Young, Rebecca K·2020·The Lancet Infectious Diseases

Abstract

BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic in 2020. Testing is crucial for mitigating public health and economic effects. Serology is considered key to population-level surveillance and potentially individual-level risk assessment. However, immunoassay performance has not been compared on large, identical sample sets. We aimed to investigate the performance of four high-throughput commercial SARS-CoV-2 antibody immunoassays and a novel 384-well ELISA. METHODS: We did a head-to-head assessment of SARS-CoV-2 IgG assay (Abbott, Chicago, IL, USA), LIAISON SARS-CoV-2 S1/S2 IgG assay (DiaSorin, Saluggia, Italy), Elecsys Anti-SARS-CoV-2 assay (Roche, Basel, Switzerland), SARS-CoV-2 Total assay (Siemens, Munich, Germany), and a novel 384-well ELISA (the Oxford immunoassay). We derived sensitivity and specificity from 976 pre-pandemic blood samples (collected between Sept 4, 2014, and Oct 4, 2016) and 536 blood samples from patients with laboratory-confirmed SARS-CoV-2 infection, collected at least 20 days post symptom onset (collected between Feb 1, 2020, and May 31, 2020). Receiver operating characteristic (ROC) curves were used to assess assay thresholds. FINDINGS: At the manufacturers' thresholds, for the Abbott assay sensitivity was 92·7% (95% CI 90·2-94·8) and specificity was 99·9% (99·4-100%); for the DiaSorin assay sensitivity was 96·2% (94·2-97·7) and specificity was 98·9% (98·0-99·4); for the Oxford immunoassay sensitivity was 99·1% (97·8-99·7) and specificity was 99·0% (98·1-99·5); for the Roche assay sensitivity was 97·2% (95·4-98·4) and specificity was 99·8% (99·3-100); and for the Siemens assay sensitivity was 98·1% (96·6-99·1) and specificity was 99·9% (99·4-100%). All assays achieved a sensitivity of at least 98% with thresholds optimised to achieve a specificity of at least 98% on samples taken 30 days or more post symptom onset. INTERPRETATION: Four commercial, widely available assays and a scalable 384-well ELISA can be used for SARS-CoV-2 serological testing to achieve sensitivity and specificity of at least 98%. The Siemens assay and Oxford immunoassay achieved these metrics without further optimisation. This benchmark study in immunoassay assessment should enable refinements of testing strategies and the best use of serological testing resource to benefit individuals and population health. FUNDING: Public Health England and UK National Institute for Health Research.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1473-3099(20)30634-4

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Cited by

See all 351

Metadata

Authors
Ainsworth, M., Andersson, M., Auckland, K., Baillie, J. K., Barnes, E., Beer, S., Beveridge, A., Bibi, S., Blackwell, L., Borak, M., Bown, A., Brooks, T., Burgess-Brown, N. A., Camara, S., Catton, M., Chau, K. K., Christott, T., Clutterbuck, E., Coker, J., Cornall, R. J., Cox, S., Crawford-Jones, D., Crook, D. W., D'Arcangelo, S., Dejnirattsai, W., Dequaire, J. M. M., Dimitriadis, S., Dingle, K. E., Doherty, G., Dold, C., Dong, T., Dunachie, S. J., Ebner, D., Emmenegger, M., Espinosa, A., Eyre, D. W., Fairhead, R., Fassih, S., Feehily, C., Felle, S., Fernandez-Cid, A., Fernandez Mendoza, M., Foord, T. H., Fordwoh, T., Fox McKee, D., Frater, J., Gallardo Sanchez, V., Gent, N., Georgiou, D., Groves, C. J., Hallis, B., Hammond, P. M., Hatch, S. B., Harvala, H. J., Hill, J., Hoosdally, S. J., Horsington, B., Howarth, A., James, T., Jeffery, K., Jones, E., Justice, A., Karpe, F., Kavanagh, J., Kim, D. S., Kirton, R., Klenerman, P., Knight, J. C., Koukouflis, L., Kwok, A., Leuschner, U., Levin, R., Linder, A., Lockett, T., Lumley, S. F., Marinou, S., Marsden, B. D., Martinez, J., Martins Ferreira, L., Mason, L., Matthews, P. C., Mentzer, A. J., Mobbs, A., Mongkolsapaya, J., Morrow, J., Mukhopadhyay, S. M. M., Neville, M. J., Oakley, S., Oliveira, M., Otter, A., Paddon, K., Pascoe, J., Peng, Y., Perez, E., Perumal, P. K., Peto, T. E. A., Pickford, H., Ploeg, R. J., Pollard, A. J., Richardson, A., Ritter, T. G., Roberts, D. J., Rodger, G., Rollier, C. S., Rowe, C., Rudkin, J. K., Screaton, G., Semple, M. G., Sienkiewicz, A., Silva-Reyes, L., Skelly, D. T., Sobrino Diaz, A., Stafford, L., Stockdale, L., Stoesser, N., Street, T., Stuart, D. I., Sweed, A., Taylor, A., Thraves, H., Tsang, H. P., Verheul, M. K., Vipond, R., Walker, T. M., Wareing, S., Warren, Y., Wells, C., Wilson, C., Withycombe, K., & Young, R. K.
Venue
The Lancet Infectious Diseases
Publisher
Elsevier BV
Published
2020-12
Volume
20
Issue
12
Pages
1390-1400
ISSN
1473-3099 (ISSN-L)
OpenAlex
W3087639085
Cited by
351
References
25
FWCI
9.54
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. https://app.cochat.ai/papers/10.1016/s1473-3099(20)30634-4
The paper
Ainsworth, M., Andersson, M., Auckland, K., Baillie, J. K., Barnes, E., Beer, S., Beveridge, A., Bibi, S., Blackwell, L., Borak, M., Bown, A., Brooks, T., Burgess-Brown, N. A., Camara, S., Catton, M., Chau, K. K., Christott, T., Clutterbuck, E., Coker, J., . . . Young, R. K. (2020). Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(20)30634-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.